We identify CDK4 as a synthetic vulnerability in colorectal cancer cells and show that dual inhibition of TNKS and CDK4 drives a potent cell cycle arrest in a range of human epithelial cancer cell lines including colon, breast and lung cancer cells. This evidence concerns the gene CDK4 and lung cancer.